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Abstract: A series of 5-aryl-3-[(2-chloroquinolin-3-yl)methylene] furan-2(3H)-
ones (3a–p) were synthesized. The required 3-(substituted benzoyl)propionic 
acids 2a–d were prepared under Friedеl–Crafts acylation reaction conditions. 
The substituted 2-chloroquinoline-3-carboxaldehydes 1a–d were synthesized 
by reaction of substituted phenylethanone oxime with phosphorus oxychloride 
in presence of dimethylformamide using the Vilsmeier–Haack reaction method. 
These compounds were screened for their anti-inflammatory and antibacterial 
activities along with their ulcerogenic and lipid peroxidation potentials. The 
compounds that showed significant anti-inflammatory activity were further 
screened for their analgesic activity. The compounds were less toxic in terms of 
ulcerogenicity as compared to a standard, which was also supported by lipid 
peroxidation studies. The antibacterial activities were performed against Sta-
phylococcus aureus and Escherichia coli. Compounds 3f, 3n and 3o showed 
significant activity against both S. aureus and  E. coli having an minimum 
inhibitory concentration (MIC) value of 6.25 μg mL-1. 
Keywords: furanone; quinoline; anti-inflammatory; analgesic; antibacterial ac-
tivity. 
INTRODUCTION 
Inflammation occurs due to the biosynthesis of pro-inflammatory prostaglan-
dins from arachidonic acid by the action of the enzyme cyclooxygenase (COX). 
In the human system, COX occurs in two isoforms, viz. COX-1 and COX-2.1 
Constitutive, COX-1 is responsible for housekeeping functions while inducible 
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COX-2 is released during tissue injury, which causes the overproduction of pros-
taglandins.2 Overexpressive COX-2 is also responsible for colon cancer. 
Drugs used for treating the signs and symptoms of inflammation are referred 
to as NSAIDs. However the traditional non-steroidal anti-inflamatory drugs 
(NSAIDs), in addition to suppressing the effects of pathological COX also inter-
fere with the housekeeping functions of the cyclo-oxygenase enzyme, which re-
sults in gastrointestinal tract (GIT) irritation, bleeding and ulceration.3 This ex-
plains why the search for novel anti-inflammatory agent is necessary and hence, 
the need to develop and screen agents which would specifically inhibit the action 
of COX-2. However, this selective COX-2 inhibition has adverse cardiovascular 
effects.4 Thus, there is a continuous need for the development of compounds 
with a safe analgesic and anti-inflammatory profile. 
Quinoline and its derivatives are an important class of pharmaceutical agents 
known to occur in several natural compounds and found to possess anti-inflam-
matory5 and analgesic6 activity in addition to other pharmacological activities.7–10 
Similarly, furanone and its derivatives have been reported to have anti-inflam-
matory,11,12 cardiotonic,13 analgesic12,14 and COX-2 inhibition15,16 activities in 
addition to antioxidant,17 cytotoxic,18 antifungal,11,12,14,19 antibacterial11,12,14,20 
and antiviral21 activities.  
Previously, the anti-inflammatory activities of a number of 3-arylidene-5- 
-(substituted phenyl)-2(3H)-furanones were studied and the results were encour-
aging.11,12,14,22,23 In view of these observations and as a part of an ongoing re-
search program on development of newer anti-inflammatory and analgesic agents, 
the synthesis and pharmacological activities of a series of 2(3H)-furanones fused 
with the quinoline moiety are reported herein. 
RESULTS AND DISCUSSION 
Chemistry 
Sixteen new compounds 3a–p were synthesized as outlined in Scheme 1. 
The required 3-(substituted benzoyl)propionic acids 2a–d  were prepared by 
reacting different substituted benzenes with succinic anhydride in presence of an-
hydrous aluminium chloride followed by acylation under Friedel–Crafts reaction 
conditions.14,22,24 The substituted 2-chloroquinoline-3-carboxaldehydes 1a–d 
were synthesized by reacting substituted phenylethanone oxime with phosphorus 
oxychloride in presence of dimethyl formamide using the Vilsmeier–Haack reac-
tion method.25,26 
5-Aryl-3-[(2-chloroquinolin-3-yl)methylene] furan-2(3H)-ones  3a–p were 
synthesized by condensing different aromatic aldehydes (1a–d) with a 3-(substi-
tuted benzoyl)propionic acids (2a–d) in presence of triethylamine and acetic an-
hydride under anhydrous conditions following a modified Perkin reaction.14,22 
Calculations of δ-values using incremental parameters for the hydrogen (semi-
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cyclic double bond) suggested the (E)-configuration. All the synthesized com-
pounds were characterized by spectroscopic data, i.e., IR, 1H-NMR, 13C-NMR 
and mass, and elemental analysis. The results are given in the supplementary 
material to this paper. 
 
Scheme 1. The reaction scheme for the synthesis of compounds 3a–p (i – hydroxylamine 
hydrochloride and sodium acetate; ii – dimethylformamide and POCl3; iii – anhydrous AlCl3 
and succinic anhydride; iv – acetic anhydride and triethylamine). 
In general, the infrared spectral data of the furanones 3a–p revealed bands at 
1790–1740 cm–1 (lactone C=O), 1610–1560 cm–1 (ArC=C), 1070–1060 cm–1 
(ArC–N) and 827–806 cm–1 (ArC–H). In the 1H-NMR spectra, all the com-
pounds showed two singlets of one proton each at around δ 6.6 and 8.2 ppm, 
which could be assigned to the ring β-H and the olefinic hydrogen of the aryli-
dene substituent. Other peaks were observed at the appropriate positions. Some 
points could be made regarding the fragmentation pattern observed in the elec-
tron impact mass spectrum. The 5-aryl-3-[(2-chloroquinolin-3-yl)methylene] fu-
ran-2(3H)-ones 3a–p gave an M+ and M+2 (isotopic peak, due to presence of 
chlorine) peak of reasonable intensities. 
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Biological evaluation 
Anti-inflammatory activity. The in vivo anti-inflammatory activity of the syn-
thesized compounds 3a–p was evaluated by the carrageenan-induced rat paw 
edema method.27 Ibuprofen was used as the standard drug for comparison (Table 
I).The anti-inflammatory activity test showed that 5-(4-bromophenyl)-3-[(2- 
-chloro-6-methoxyquinolin-3-yl)methylene] furan-2(3H)-one (3o)  exhibited the 
maximum anti-inflammatory activity (68.9 % inhibition) in addition to 5-(4-bro-
mophenyl)-3-[(2,6-dichloroquinolin-3-yl)methylene] furan-2(3H)-one (3n), 5-(4-
methylphenyl)-3-[(2-chloro-6-methoxyquinolin-3-yl)methylene] furan-2(3H)-one 
(3g) and 5-(4-bromophenyl)-3-[(2-chloro-6-methylquinolin-3-yl)methylene] fu-
ran-2(3H)-one (3p), showing 59.03, 56.62 and 53.01 % inhibition, respectively. 
The results are presented in Table I. 
TABLE I. Anti-inflammatory and analgesic activity along with the ulcerogenic and lipid 
peroxidation effect of the synthesized compounds 3a–p 
Compound 
% Inhibition ± SEM
a
Severity 
index
b 
Lipid peroxidation
c
nmol MDA mg
-1 
protein 
Analgesic activity 
(writhing test)
b 
After 2 h  After 3 h  No. of writhes 
per 30 min 
Protection 
% 
Control – –  0.00±0.00 0.24±0.002
b 83±1.31  – 
Ibuprofen 67.7±2.05  80.8±2.60 0.83±0.36 0.73±0.001
a 29±1.15  65.06 
3a  9.5±1.79 16.0±1.81 0.4±0.10 0.39±0.005
ab –  – 
3b 18.6±3.16  23.4±2.87 0.3±0.12 0.40±0.005
ab    
3c 16.4±1.72  22.8±0.42 0.33±0.12 0.35±0.001
ab –  – 
3d 18.8±2.83  29.7±3.39 0.5±0.27 0.39±0.007
ab –  – 
3e 26.6±4.34  36.0±3.22 0.52±0.36 0.54±0.001
ab –  – 
3f 28±2.74  50.4±1.73 0.41±0.1 0.40±0.002
ab –  – 
3g 34.1±4.16  53.8±1.38 0.16±0.12 0.36±0.014
ab 36±1.89  56.62 
3h 44.9±5.22  50.0±2.28 0.41±0.1 0.41±0.002
ab –  – 
3i 10.4±3.86  19.9±3.06 0.46±0.4 0.55±0.001
ab –  – 
3j 33.7±2.61  39.7±2.80 0.5±0.27 0.42±0.001
ab –  – 
3k 21.5±4.01  36.6±3.51 0.48±0.36 0.53±0.017
ab –  – 
3l 20±1.97  37.0±3.27 0.5±0.27 0.49±0.001
ab –  – 
3m 26.6±3.98  34.5±3.54 0.43±0.36 0.58±0.001
ab –  – 
3n 38.2±1.97  56.3±3.49 0.16±0.12 0.29±0.001
ab 34±1.24  59.03 
3o 48.6±3.69  68.9±3.07 0.25±0.12 0.38±0.002
ab 33±1.31  60.24 
3p  42.4±1.79 52.0±2.42 0.2±0.12 0.33±0.006
ab 39±1.94  53.01 
aRelative to the standard (ibuprofen) and data were analyzed by one-way ANOVA followed by the Tukey test 
for n = 6; 
brelative to their respective control and the data were analyzed by one-way ANOVA followed by the 
Tukey test for n = 6; 
clipid peroxidation activity is expressed as nmoles of MDA mg
-1 protein. “±” indicates the 
minimum and maximum variation in the average values. “–” indicates not tested 
Based on the above observations, the following structure–activity relation-
ship can be concluded:  
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i) presence of an electronegative group on phenyl moiety of the furanone 
ring increases the anti-inflammatory activity as compared to that of an electro-
positive group; 
ii) an increase in number of electropositive groups on the phenyl moiety of 
the furanone ring further decreases the activity; 
iii) the presence of a methoxy group on the quinoline nucleus showed 
maximum activity; 
iv) replacement of the methoxy group by a methyl group decreases the ac-
tivity. 
All the synthesized compounds were further tested for their ulcerogenic and 
lipid peroxidation effects. The test compounds (3o, 3n, 3g and 3p) that exhibited 
an above 65 % ibuprofen edema inhibition were further evaluated for their anal-
gesic activity. 
Analgesic activity. The analgesic activity was evaluated by the acetic acid-
induced writhing test.28 The results indicated that compounds 3o and 3n showed 
60.24 and 59.03 % activity, respectively, which were comparable to that of the 
standard ibuprofen (65.06 %). Compounds 3g and 3p also showed good anal-
gesic activity (Table I). 
Acute ulcerogenesis. The synthesized compounds were screened for their 
ulcerogenic activity by the Cioli et al. method.29 Compounds 3o and 3n showed 
a severity index of 0.25±0.12 and 0.16±0.12, respectively, which were much 
lower as compared to that of ibuprofen (0.83±0.36). The results indicated that the 
compounds were less toxic in terms of ulcerogenicity as compared to standard, 
which was also supported by lipid peroxidation studies (Table I). 
Lipid peroxidation. All the compounds screened for ulcerogenic activity 
were also analyzed for lipid peroxidation by the Ohkawa et al. method.30 The 
lipid peroxidation was measured as nmoles of malondialdehyde (MDA) mg–1 of 
protein. Ibuprofen exhibited high lipid peroxidation 0.73±0.001 whereas control 
group showed 0.24±0.002. It was found that all the furanone derivatives fused 
with quinoline ring showed less ulcerogenic activity along with reduced lipid 
peroxidation (Table I). 
Antibacterial activity. All the compounds tested for antimicrobial activity 
showed inhibition of growth. Compounds 3f, 3n and 3o showed significant acti-
vity against both Staphylococcus aureus and Escherichia coli with a minimum 
inhibitory concentration (MIC) value of 6.25 μg mL–1 (Table II). Of the sixteen 
new compounds, two compounds, 3i and 3j were found to be more active against 
S. aureus with an MIC value of 6.25 μg mL–1. Analyses of the results indicated 
that: 
i) the presence of a chloro group on the quinoline nucleus induced selectivity 
of the furanone towards inhibition of S. aureus; 
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ii) the presence of an electropositive group on the phenyl moiety of the fura-
none ring induced inhibition of S. aureus. However, an electronegative group fa-
voured inhibition of E. coli. 
TABLE II. Antibacterial activity, MIC / μg mL-1, results of the 2(3H)-furanones (the studies 
were performed in triplicate) 
Compound  S. aureus  E. coli 
Nitrofurazone 12.5±0.0 6.25±0.0 
3a  133.37±16.67 167.67±33.34 
3b 50±0.0  50±0.0 
3c 133±33.34  50±0.0 
3d 133±33.34  166±33.34 
3e 25±0.0  50±0.0 
3f 6.25±0.0  6.25±0.0 
3g 12.5±0.0  25±0.0 
3h 25±0.0  50±0.0 
3i 6.25±0.0  12.5±0.0 
3j 6.25±0.0  12.5±0.0 
3k 25±0.0  50±0.0 
3l 12.5±0.0  25±0.0 
3m 12.5±0.0  12.5±0.0 
3n 6.25±0.0  6.25±0.0 
3o 6.25±0.0  6.25±0.0 
3p  12.5±0.0 25±0.0 
EXPERIMENTAL 
Chemistry 
Chemicals were purchased from Merck and Sigma-Aldrich as synthesis grade and were 
used without further purification. Melting points were determined by the open tube capillary 
method and are uncorrected. The purity of the compounds was checked by thin layer chroma-
tography (TLC) on silica gel G plates (Merck No. 5544) using toluene:ethyl acetate:formic 
acid (5:4:1) as the solvent system and the spots were located either under ultraviolet light or 
through exposure to iodine vapour. The IR spectra were measured as potassium bromide pel-
lets using a Perkin-Elmer 1725X spectrophotometer. The 1H-NMR spectra were recorded on 
Bruker spectrospin DPX-300 MHz in CDCl3 with tetramethylsilane (TMS) as an internal 
standard; chemical shifts (δ) are reported in parts per million (ppm) downfield from TMS. 
Mass spectra were recorded at 70 eV on a Jeol JMS-D 300 instrument fitted with a JMS 2000 
data system. Spectral data are consistent with the assigned structures. Elemental analyses were 
performed on a Perkin-Elmer model 240 analyzer (C, H, N) and were found within the range 
of ± 0.4 % of the theoretical values. 
General procedure for the synthesis of 1-(4-substituted phenyl)ethanone oximes  
The 1-(4-substituted phenyl)ethanone oximes were synthesized from different substituted 
acetophenones (0.1 mol), hydroxylamine hydrochloride (0.12 mol) and sodium acetate (0.12 
mol) using the method reported by Cohn et al.25 
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General procedure for the synthesis of the 2-chloroquinolin-3-carboxaldehydes 1a–d 
To dimethylformaldehyde (0.15 mol) cooled to 0 °C, freshly distilled phosphorous oxy-
chloride (0.35 mol) was added dropwise under stirring, then the respective oxime (0.05 mol) 
was added portion-wise. The reaction mixture was heated at 60 °C for 16 h. It was then 
poured into ice water (300 mL) and stirred for 30 min. The 2-chloroquinoline-3-carboxalde-
hyde was filtered and recrystallized from ethyl acetate.25,26 
General procedure for the synthesis of 3-(substituted benzoyl)propionic acids 2a–d 
The 3-(substituted benzoyl)propionic acids were synthesized according to a previously 
reported method14,22,24 using dry substituted-benzene (50 mL) under anhydrous conditions in 
presence of anhydrous aluminium chloride (0.15 mol) and succinic anhydride (0.1 mol). The 
obtained product was crystallized from aqueous ethanol to give a colourless compound that 
gave effervescence with sodium bicarbonate.  
General procedure for the synthesis of 3-[(2-chloroquinolin-3-yl)methylene]-5-(substituted 
phenyl) furan-2(3H)-ones 3a–p 
Each compound 2a–d (3 mmol) and each compound 1a–d (equimolar, 3 mmol) were 
fused together in presence of acetic anhydride (5–8 drops) in a round-bottom flask for half an 
hour. To this fused mixture, triethylamine (2 drops) was added and the heating on a heating 
mantle was continued for a further 15 min. After the completion of reaction, the obtained solid 
mass was crystallized from methanol and gave the desired products. 
Biological evaluation 
Animals. The Wistar rats and albino mice used in the present study were housed and kept 
in accordance with the Hamdard University Animal Care Unit, which applies the guidelines 
and rules laid down by the Committee for the Purpose of Control and Supervision of Experi-
ments on Animals (CPCSEA), Ministry of Social Justice and Empowerment, Government of 
India. Wistar rats and albino mice of either sex (Hamdard University, Animal House, New 
Delhi, India), weighing 180–200 g (12 weeks) and 22–25 g (8 weeks), respectively, were 
used. The animals were housed in groups of six and acclimatized to ambient conditions for at 
least 2 days before the experiments. Food and water were freely available up to the time of the 
experiments. The food was withdrawn on the day before the experiment, but free access to 
water was allowed. 
Anti-inflammatory activity. The synthesized compounds were evaluated for their anti-in-
flammatory activity using the carrageenan-induced paw edema method of Winter et al.27 The 
animals were randomly divided into groups of six. Group I was kept as control, and received 
only 0.5 % carboxymethyl cellulose (CMC) solution. Group II was kept as the standard and 
received ibuprofen. Carrageenan solution (0.1 % in sterile 0.9 % NaCl solution) in a volume 
of 0.1 mL was injected subcutaneously into the sub-plantar region of the right hind paw of 
each rat, 30 min after the administration of the test compounds (20 mg kg-1 p.o.) and the 
standard drugs. The paw volume was measured by saline displacement shown on the screen of 
digital plethysmometer (Ugo Basile) at 2 and 3 h after carrageenan injection. The edema vo-
lume in the control group (Vc) and edema volume in the groups treated with test compounds 
(Vt) was measured and the percentage inhibition of edema was calculated using the formula: 
  Anti-inflammatory activity (% inhibition) = 100((Vc – Vt) / Vc) 
where Vc is the paw volume of the control group and Vt is the paw volume of the test group. 
Analgesic activity. The compounds which showed anti-inflammatory activity above 75 % 
of the ibuprofen inhibition were screened for analgesic activity. The determination of the 
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analgesic activity was realized by the acetic acid-induced writhing method.28 Mice were 
divided into groups with six in each. Group I was taken as the control and received CMC 
suspension only, group II received the reference drug ibuprofen and the other groups were 
treated with the test drugs (20 mg kg-1) suspended in 1.0 % CMC orally. A 1 % aqueous acetic 
acid solution (0.1 mL) was used as writhing-inducing agent. The acetic acid solution was in-
jected intraperitoneally 3 h after the treatment with the reference and test drugs to the various 
groups, respectively, and writhings were noted for 10–15 min after acetic acid administration. 
Acute ulcerogenesis. Acute ulcerogenesis test was performed according to the method of 
Cioli et al.29 Wistar rats were divided into different groups consisting of six animals in each 
group. Ulcerogenic activity was evaluated after p.o. administration of test compounds or 
ibuprofen at a dose of 60 mg kg-1. The control rats received p.o. administration of the vehicle 
(suspension of 1 % carboxymethyl cellulose). Food but not water was removed 24 h before 
administration of the test compounds. After drug treatment, the rats were fed with a normal diet 
for 17 h and then sacrificed. The stomach was removed and opened along the greater 
curvature, washed with distilled water and cleaned gently by dipping in normal saline. The 
mucosal damage was examined by means of a magnifying glass and compared with that after 
ibuprofen administration. For each stomach, the mucosal damage was assessed according to 
the following scoring system: 0.5: redness, 1.0: spot ulcers, 1.5: hemorrhagic streaks, 2.0: 
ulcers > 3 but < 5, 3.0: ulcers > 5.  
The mean score of each treated group minus the mean score of the control group was 
regarded as the severity index of gastric mucosal damage. 
Lipid peroxidation. Lipid peroxidation in the gastric mucosa was determined according 
to the method of Ohkawa et al.30 After screening for ulcerogenic activity, the gastric mucosa 
was scraped with two glass slides and 10 % of that tissue was homogenized at 10,000 rpm in 
1.8 mL of 1.15 % ice-cold KCl solution. 1 mL of suspension medium was taken from the 
supernatant, 0.5 mL of 30 % trichloroacetic acid (TCA) followed by 0.5 mL of 0.8 % thiobar-
bituric acid (TBA) reagent were added to it. The tubes were covered with aluminium foil and 
kept in a shaking water bath for 30 min at 80 °C. After 30 min, the tubes were taken out and 
kept in ice-cold water for 10 min. These were then centrifuged at 3000 rpm for 15 min. The 
absorbance of the supernatant was read at 540 nm at room temperature against the blank on a 
UV spectrophotometer. 
The standard curve used for estimating the concentration of MDA was prepared by using 
1,1,3,3-tetraethoxypropane. The results are presented as nmol MDA mg-1 of protein. 
Antibacterial activity. The antibacterial studies were performed on the synthesized com-
pounds against the microorganisms S. aureus and E. coli in meat peptone agar medium at a 
concentration of 100 μg ml-1. Compounds inhibiting growth of one or more of the micro-
organisms were further tested for their MIC value. The test was performed according to the 
turbidity method31 using nitrofurazone as the standard. 
SUPPLEMENTARY MATERIAL 
Аnalytical and spectral data of synthesized compounds are available electronically from 
http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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ИЗВОД 
СИНТЕЗА ХИНОЛИН-ВЕЗАНИХ ФУРАН-2(3Н)-ОНА КОЈИ ИМАЈУ 
АНТИИНФЛАМАТОРНА И АНТИБАКТЕРИЈСКА СВОЈСТВА 
УЗ СМАЊЕНУ ГАСТРОИНТЕСТИНАЛНУ ТОКСИЧНОСТ И 
ЛИПИДНУ ПЕРОКСИДАЦИЈУ 
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Синтетисана је серија 5-арил-3-[(2-хлорохинолин-3-ил)метилен] фуран-2(3H)-она (3a–
p). Потребне 3-(супституент-бензоил)-пропионскe киселине 2a–d су добијене Friedеl–Crafts- 
-овом реакцијом ациловања. Супституисани 2-хлорохинолин-3-карбалдехиди 1a–d су син-
тетисани у реакцији супституисаних фенилетанон-оксима са фосфор-оксихлоридом, у при-
суству диметил-формамида, применом Vilsmeiеr–Haack-овог реакционог метода. За ова једи-
њења је утврђивана антиинфламаторна, антибактеријска и улцерогена активност, као и спо-
собност да изазову липидну пероксидацију. Једињења која су показала значајну антиинфла-
маторну активност даље су испитивана као аналгетици. Једињења су испољила мању токсич-
ност у поређењу са стандардним препаратима, у погледу улцерогености и липидне перокси-
дације. Антибактеријска активност је тестирана спрам S. aureus и E. coli. Једињења 3f, 3n и 
3o су показала значајну активност спрам обе бактерије, уз минималну инхибиторну концен-
трацију од 6,25 μg mL-1. 
(Примљено 31. јануара, ревидирано 4. маја 2011) 
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